Gubra releases its results for the first quarter of 2024. For the CRO business, performance was strong with organic revenue growth of 51% year-over-year. Within the D&P business, there was significant ...
Gubra announces an upgrade to its full-year 2024 financial outlook. Organic revenue growth for the CRO business is now expected to be 15-20% (previously 10-15%) and adjusted EBIT-margin is expected ...
From the Department of Cardiovascular Pathology, Armed Forces Institute of Pathology, Washington, DC. Conclusions—ARVC is a familial arrhythmogenic disease characterized by fibrofatty replacement of ...